ALW-II-41-27,
ALW-II-41-27,
1186206-79-0,
N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)-5-(thiophen-2-yl)nicotinamide,
MLS002232274,
CHEMBL556140,
SCHEMBL20136698,
DTXSID80655254,
ALW II-41-27,
BDBM163701,
HMS2043H01,
HMS2218G07,
HMS3333E20,
BCP26205,
EX-A2618,
ZINC42966573,
Eph receptor tyrosine kinase inhibitor,
CS-1203,
NCGC00390558-01,
HY-18007,
SMR001307828,
A12493,
W-6044,
Benzamide, N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]-,
N-[5-({4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbamoyl)-2-methylphenyl]-5-(thiophen-2-yl)pyridine-3-carboxamide,
N-[5-({4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbamoyl)-2-methylphenyl]-5-(thiophen-2-yl)pyridine-3-carboxamide (6),
HYWXBDQAYLPMIX-UHFFFAOYSA-N,
N-[5-[[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]carbamoyl]-2-methylphenyl]-5-thiophen-2-ylpyridine-3-carboxamide,